Indivior Pharmaceuticals, Inc. stock analysis SPUN.US

Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing medications for the treatment of opioid use disorder (OUD). Its core business is the creation and commercialization of buprenorphine-based prescription drugs, with its leading products being SUBLOCADE, a once-monthly extended-release injectable form of buprenorphine, and SUBOXONE Film, a buprenorphine / naloxone sublingual film.

In addition to its core products, Indivior markets other formulations including SUBOXONE Tablet (buprenorphine / naloxone), SUBUTEX Tablet (buprenorphine alone), and had previously supported OPVEE, a nalmefene nasal spray approved for opioid overdose reversal, though sales and marketing support for OPVEE in the U.S. have been discontinued, with the company continuing distribution upon request and meeting regulatory obligations.

Indivior operates globally, but its revenue is heavily concentrated in the United States, which accounted for over 80% of its net revenues in recent years. Its products are sold in Canada, Australia, France, and Germany, and - until recently - other European countries as well; however the company is restructuring its Rest-of-World operations and exiting certain non-U.S. markets. It maintains a manufacturing facility in Hull, U.K. for its fine chemicals operations, along with clinical development and regulatory operations across regions.